Drug intelligence / Profile preview

anti-IGSF11 antibody

Development stage
Preclinical
Lead developer
iOmx Therapeutics
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Anti-IGSF11 antibody refers non-specifically to antibodies directed against **immunoglobulin superfamily member 11**. In the therapeutic context provided, the clearest identified example is **SG7**, a preclinical monoclonal antibody that blocks the **IGSF11-VISTA** immune-checkpoint interaction and is being explored as a cancer immunotherapy for solid tumors. Available information indicates antitumor activity in mouse melanoma and colon carcinoma models, including enhanced activity in combination with anti-PD-1 therapy, but no clearly established commercial brand name, manufacturer, or confirmed clinical-stage development program was identified.

Other names
anti-IGSF11 antibodyanti-IGSF-11 antibodyanti-IGSF 11 antibodyanti-IGSF11 monoclonal antibodyanti-IGSF-11 monoclonal antibodyanti-IGSF 11 monoclonal antibodyIGSF11 antibodyIGSF-11 antibodyIGSF 11 antibody
02

Targets

CTA (Cancer-testis antigens)

Beyond the preview

Go deeper on anti-IGSF11 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-IGSF11 antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call